MedTrace Logo

Plasma Diurnal Variation in and Absorption of EPA and DHA

NCT02661698 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-11-08

No results posted yet for this study

Summary

This study will evaluate the absorption of two different dietary supplements containing the omega 3 fatty acids eicosapentaenoic acid and docosahexaenoic acid over 24 hours via venous blood plasma following a single dose taken at bed time. In addition, the circadian rhythm of fatty acid metabolism will also be assessed following the placebo intervention.

Conditions

  • Lipid Absorption and Metabolism

Interventions

DIETARY_SUPPLEMENT

Omega-3 oil: DHA enriched

3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA

DIETARY_SUPPLEMENT

Placebo

3 x 1 g capsules Placebo: olive oil

DIETARY_SUPPLEMENT

Omega-3 oil: EPA enriched

3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA

Sponsors & Collaborators

  • Pronova BioPharma

    collaborator INDUSTRY

  • Northumbria University

    lead OTHER

Principal Investigators

  • Philippa A Jackson, PhD · Northumbria University

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661698 on ClinicalTrials.gov